An implantable medical device having a soft tissue interfacing surface comprises at least one soft actuatable capsule having a soft tissue interfacing deflectable membrane configured for cyclical deflection upon actuation of the capsule to modulate the biomechanics of the soft tissue interface during use. The actuatable capsule may comprise an actuation chamber containing a first fluid, a therapeutic chamber containing a second fluid, a deflectable membrane separating the actuation chamber and therapeutic chamber, and an actuation conduit in fluidic communication with the actuation chamber for pneumatic actuation of the actuation chamber. The therapeutic chamber comprises the soft tissue interfacing deflectable membrane which is configured to cyclically deflect during actuation of the capsule and modulate the biomechanics of the soft tissue interface by altering one or more of strain, fluid flow and cellular activity in peri-implant tissue at the soft tissue interface. Methods of reducing fibrotic encapsulation of an implantable medical device are also described.

Magnetosomes for use in a sequential laser radiation medical treatment, wherein the magnetosomes are administered to a body part of an individual. In a first step, the magnetosomes are irradiated by a laser radiation, and in a second step, the magnetosomes are irradiated by a laser radiation of lower power than in the first step or no laser irradiation of the magnetosomes is performed. The sequence of the first step and second step is repeated at least once.

The invention relates to electrically-heatable plasters which comprise a self-adhesive skin contact layer, an electrically-conductive textile fabric in which electrically-conductive fibres are in contact with one another, as a heating element, and optionally at least one active substance, as well as to a method for production and the use of same for local heat therapy and/or transdermal application of active substances.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an integrin inhibitor. In particular, the disclosure features the topical treatment of sections and subsections of the gastrointestinal tract by integrin inhibitors (like vedolizumab) using an ingestible device that can detect its whereabouts in the Gl tract by using reflectance and which is programmed to release the drugs at a given site or proximal thereto, to treat gastrointestinal inflammatory diseases. The device has hardware storage devices with instructions on board to determine the location and release the formulations. Combination therapies are claimed as well in which the integrin inhibitor is added systemically and another agent (e.g. JAK inhibitor, TNF-alpha inhibitor or IL-12/IL-23 inhibitor) is added topically by means of the ingestible device. The topical administration is said to reduce the side effects associated with systemic treatment.

Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

The present invention relates to antigen binding sites, compositions and uses thereof in the treatment of conditions associated with pathogenic proteins. In one example the condition is Alzheimer's disease.

A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.

The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets.

A method of inducing cell death in a subject includes administering to the subject a plurality of cell targeted nanobubbles that are internalized by the target cell and insonating nanobubbles internalized into the target cell with ultrasound energy effective to promote inertial cavitation of the internalized nanobubbles and apoptosis and/or necrosis of the target cell.

Disclosed is an iontophoresis-based patch type medicine absorption device for allowing a medicine for medical treatment or a functional substance for skin care to be effectively absorbed into a user's skin by causing iontophoresis on the user's skin through a conductive patch. The iontophoresis-based patch type medicine absorption device for allowing the medicine for medical treatment or the functional substance for the skin care to be absorbed into the user's skin by the iontophoresis includes a medicine absorption device body that generates power to cause the iontophoresis. The medicine absorption device body includes a power circuit that is provided in an interior space of a body and that includes a power unit that generates the power for the iontophoresis and one or more electrodes to which the power is applied, and a bridge that is provided so as to be combinable with the body and that receives the power through the one or more electrodes. The bridge includes a bridge body provided so as to be combinable with the body and a plurality of bridge legs arranged along a circumferential direction of the bridge body and formed of a conductive material.